Kevin Buchi
And finally in this week’s rather international People’s Column we head over to Australia where biotech company Benitec Biopharma Limited has appointed Kevin Buchi to its Board of Directors.
Buchi, who served as Chief Executive Officer of Cephalon through its $6.8 billion acquisition by Teva in October 2011, is also a member of the boards of Stemline Therapeutics, Forward Pharma and Alexza Pharmaceuticals.
Benitec’s Chairman, Mr. Peter Francis, said of the appointment: “Kevin's impressive track record in the international biotechnology and pharmaceutical industry over 30 years provides Benitec with significant additional business development strength, and importantly, networking capacity in the United States and Europe.”